ITA - Clinical Study Comparing ARIMIDEX™ with NOLVADEX™ in Women with Breast Cancer treated with NOLVADEX for at least 2 years
Study identifier:1033IT/0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open Randomised Clinical Study Comparing ARIMIDEX™ with NOLVADEX™ as Adjuvant Therapies in Post-menopausal Women with Breast Cancer Already Being Treated with NOLVADEX for at Least Two Years
Medical condition
Breast Cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Anastrozole, Tamoxifen
Sex
Female
Actual Enrollment
448
Study type
Interventional
Age
N/A - 75 Years
Date
Study Start Date: 01 Mar 1998
Primary Completion Date: -
Study Completion Date: 01 May 2006
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
National Cancer Research Institute
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Anastrozole | Drug: Anastrozole oral Other Name: Arimidex Other Name: ZD1033 |
| Active Comparator: 2 Tamoxifen | Drug: Tamoxifen oral Other Name: Nolvadex |
Contacts
Investigators
Principal Investigator
AstraZeneca Arimidex Medical Science Director
AstraZeneca
